3 Reasons Pfizer Investors Shouldn't Be Concerned About the Q1 Revenue Dip
Pfizer, Inc. (NYSE:PFE) reported its first-quarter results before the market opened on Tuesday. The big drugmaker's revenue of $12.8 billion reflected a 2% drop from the prior-year period.
Falling sales isn't usually a good sign. Should Pfizer investors be concerned?
Falling sales isn't usually a good sign. Should Pfizer investors be concerned?